youtube
Hims and Hers Health is teaming up with Eli Lilly to bring weight loss treatments directly to self-pay patients, offering options like Foundayo and Zepbound at competitive monthly rates. While Eli Lilly continues to outpace competitors like Novo Nordisk with an impressive 45.5% revenue growth and an 83% gross margin, Hims and Hers holds strong with 28% top-line growth and a 69.5% gross margin. Seeking Alpha Quant Ratings currently grade both companies as a Hold, highlighting a balanced risk-reward profile as direct-to-consumer partnerships reshape the massive GLP-1 market.
|
